What is Therapixel?
Therapixel is recognized as a leading French software company that applies artificial intelligence to medical imaging. This specialization places the company at the forefront of technological innovation within the healthcare sector, aiming to enhance diagnostic accuracy and efficiency through advanced AI algorithms. The company's focus on AI in medical imaging positions it to address critical needs in radiology and other diagnostic fields, potentially improving patient outcomes and streamlining clinical workflows.
How much funding has Therapixel raised?
Therapixel has raised a total of $20.2M across 3 funding rounds:
Private Equity
$644K
Series A
$4M
Series B
$15.6M
Private Equity (2015): $644K with participation from PACA Investissement
Series A (2019): $4M, investors not publicly disclosed
Series B (2022): $15.6M supported by Feedaxess, M Capital Partners, Région Sud Investissement, Omnes Capital, CapHorn Invest, Verve, Sham, and IT-Translation
Key Investors in Therapixel
PACA Investissement
PACA Investissement is a Marseille-based entity with over a decade of experience in real estate investment, offering comprehensive services for individuals and businesses in the Provence-Alpes-Côte d'Azur region. Their expertise spans market analysis, property selection, rental management, and advisory services, including opportunities in hotel real estate.
Feedaxess
Crédit Mutuel Equity is an investment firm dedicated to creating financial and extra-financial value through long-term capital investment, supporting business leaders in transforming their models with a focus on human capital and collaboration.
M Capital Partners
M Capital Partners is an independent, entrepreneurial investment company providing equity and quasi-equity financing, along with continuous support to accelerate the growth of French companies.
What's next for Therapixel?
With the recent major strategic investment and substantial overall capital, Therapixel is poised for accelerated growth and further development of its AI-powered medical imaging solutions. This significant backing suggests a strategic expansion phase, likely involving scaling operations, enhancing research and development efforts, and potentially broadening market reach. The company's trajectory indicates a strong focus on leveraging its technological advancements to capture a larger share of the rapidly evolving medical technology market, with future endeavors likely centered on refining its AI capabilities and forging new partnerships within the healthcare ecosystem.
See full Therapixel company page
